Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 14, 2026Open Forum Infectious DiseasesOpen Access

P-1188. Incidence and Risk Factors for Infections in Patients with B-cell Lymphoma Treated with Bispecific Antibodies

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDong Hyun KimYKYoungil KohHJHyeon Jae Jo

Discussion

Loading...

Member takes

Overview

Longitudinal cohort study shows high infection rates in B-cell lymphoma patients on bispecific antibodies, suggesting need for prevention strategies.

Key Points

  • To investigate the incidence and risk factors for infections in B-cell lymphoma patients receiving bispecific antibody therapy.
  • Conducted a single-center, longitudinal cohort study
  • Included B-cell lymphoma patients treated with CD3×CD20 bispecific antibodies
  • Collected data on clinical characteristics, lymphoma type, and infection episodes
  • Performed multivariate Fine and Gray model analysis to identify risk factors
  • Identified 143 infection episodes, with 61.5% being grade ≥3
  • Lower respiratory tract infections were most common (44.1%)
  • Cumulative incidence of any infection reached 75.6% at 24 months
  • Neutropenia and hypogammaglobulinemia were significant risk factors, with hypogammaglobulinemia as an independent risk for grade 3–5 infections

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6966e70e13bf7a6f02bff484https://doi.org/10.1093/ofid/ofaf695.1381
View Full Paper
Ask AI
Bookmark
Share